Sign In
Buy IRON
$70.35
+2.35 (+3.46%)
At Close: Jun 03, 2026
Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now
11:39am, Tuesday, 25'th Jul 2023
Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul
Disc Medicine: Soaring On EPP Data Release, Reality May Bite On Limited Market Opportunity
03:32pm, Friday, 09'th Jun 2023
Disc Medicine stock has shown outstanding growth since the company joined the Nasdaq in December last year, gaining nearly 250%. The company released data today from a Phase 2 study of lead candidate
Why Shares of Disc Medicine Opco Climbed This Week
03:10pm, Thursday, 01'st Jun 2023
Disc Medicine is a clinical-stage biopharmaceutical company specializing in treating blood disorders. The company's lead therapy, bitopertin, is in phase 2 trials to treat a rare inherited blood disor
Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable
09:54am, Friday, 05'th May 2023
Disc Medicine, Inc. (IRON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
08:30am, Friday, 21'st Apr 2023
WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why
09:55am, Wednesday, 19'th Apr 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Disc Medicine, Inc. (IRON) could be a great choice. It is one of the several stocks that passed through our "Re
7 Short-Squeeze Stocks for Bold Contrarians to Consider
12:22pm, Monday, 21'st Nov 2022
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
11:17am, Tuesday, 12'th Apr 2022
Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision
Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside
01:42pm, Wednesday, 15'th Dec 2021
H.C. Wainwright initiated coverage of Gemini Therapeutics Inc (NASDAQ: GMTX) with a Buy rating and $20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can ser
Gemini Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 11'th Nov 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular de
Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings?
09:57am, Wednesday, 10'th Nov 2021
Gemini Therapeutics (GMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GMTX Stock: Why It Fell This Week
03:06pm, Wednesday, 06'th Oct 2021
The stock price of Gemini Therapeutics Inc (NASDAQ: GMTX) fell over 10% this week. This is why it happened.
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
08:30am, Friday, 10'th Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular de
Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?
10:39am, Monday, 30'th Aug 2021
Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular deg
